Looking at the filing, I can see this is a 10-K for Enanta Pharmaceuticals, Inc. for the fiscal year ended September 30, 2026, filed on November 18, 2026. The ticker is ENTA on Nasdaq. Let me extract the key facts carefully. Key facts from the filing: - Fiscal year ended September 30, 2026 - Common stock trading symbol: ENTA on Nasdaq - Aggregate market value of common stock held by non-affiliates as of March 31, 2026: $264,303,817, based on last reported sale price of $12.63 per share - Shares outstanding as of November 6, 2026: 29,158,815 - Classified as non-accelerated filer and smaller reporting company - Revenue dependent on AbbVie's MAVYRET/MAVIRET sales (glecaprevir/pibrentasvir) - Phase 2b/3 study of zelicapavir in adults at high risk of severe outcomes from RSV infection mentioned - Part III info to be incorporated by reference from 2027 Annual Meeting proxy statement

Enanta Pharmaceuticals, Inc. filed its Annual Report on Form 10-K with the SEC on November 18, 2026, covering the fiscal year ended September 30, 2026, disclosing financial and operational details including share count, market capitalization, and pipeline status.

Key Highlights

  • Shares outstanding: As of November 6, 2026, the company reported 29,158,815 shares of common stock outstanding.
  • Non-affiliate market value: The aggregate market value of common stock held by non-affiliates was $264,303,817, based on a last reported sale price of $12.63 per share as of March 31, 2026.
  • Filer status: Enanta is classified as a non-accelerated filer and a smaller reporting company, according to the filing.
  • Revenue dependence: The company disclosed that its revenues for the next several years are "substantially dependent upon AbbVie's success selling MAVYRET/MAVIRET," which includes Enanta's protease inhibitor glecaprevir, for the treatment of HCV.
  • Pipeline focus: The filing identifies a Phase 2b/3 study of zelicapavir in adults at high risk of severe outcomes from RSV infection as a key development program.
  • Funding risk: The company stated it "will require substantial additional funding to achieve our goals" and that failure to obtain funding "could force us to delay, limit, reduce or terminate some or all of our product development efforts."

Enanta's FY2026 10-K: Pipeline, Revenue Dependence, and Funding Needs

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), headquartered at 4 Kingsbury Avenue, Watertown, Massachusetts, filed its Annual Report on Form 10-K for the fiscal year ended September 30, 2026. The filing describes Enanta as a clinical-stage company whose near-term revenue base remains concentrated in royalties and collaboration income tied to AbbVie's HCV regimen. According to the filing, revenues "for the next several years are substantially dependent upon AbbVie's success selling MAVYRET/MAVIRET," the HCV combination product that incorporates Enanta's protease inhibitor glecaprevir.

On the pipeline side, the filing highlights a Phase 2b/3 study of zelicapavir, targeting adults at high risk of severe outcomes from RSV infection, as a central development program. The company disclosed that it will require substantial additional funding, and that an inability to secure such funding could force it to "delay, limit, reduce or terminate some or all of our product development efforts, including our Phase 2b/3 study of zelicapavir." The filing also noted that Part III information will be incorporated by reference from the company's Definitive Proxy Statement for the 2027 Annual Meeting of Stockholders, or provided by amendment if the proxy is not filed within 120 days after the September 30, 2026 fiscal year end.

As of November 6, 2026, the company reported 29,158,815 shares of common stock outstanding, with a par value of $0.01 per share. The aggregate market value of shares held by non-affiliates stood at $264,303,817, calculated using a last reported sale price of $12.63 per share as of March 31, 2026, the last business day of the company's most recently completed second fiscal quarter. The filing contains forward-looking statements that, according to the company's own cautionary language, "are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors."

What Was Disclosed

Enanta Pharmaceuticals filed its fiscal year 2026 annual report, disclosing 29,158,815 shares outstanding, a non-affiliate market value of $264,303,817, revenue dependence on AbbVie's MAVYRET/MAVIRET HCV franchise, and a Phase 2b/3 RSV program centered on zelicapavir.